Literature DB >> 2514171

Synergy of Nocardia rubra cell wall skeleton and interleukin 2 in the in vivo induction of murine lymphokine-activated killer cell activity.

I Kawase1, K Komuta, T Shirasaka, H Hara, Y Tanio, M Watanabe, S Saito, T Ikeda, T Masuno, S Kishimoto.   

Abstract

Combination of an ip injection of Nocardia rubra cell wall skeleton (N-CWS) and 3 daily sc injections of human recombinant interleukin 2 (rIL 2) into C3H/HeN mice resulted not only in a significant increase in the number of peritoneal cells (PC) but also in a potent induction of their lymphokine-activated killer (LAK) activity, compared with results obtained with N-CWS or rIL 2 alone. The augmented LAK activity of PC was mediated by nonadherent, nonphagocytic, Thy-1.2+(-)- and asialo GM1+ cells. Nonadherent PC induced by an ip injection of N-CWS bound more 125I-labeled rIL 2 than did normal, nonadherent PC, and generated high LAK activity when cultured overnight with rIL 2. In contrast, normal, nonadherent PC responded only weakly to the overnight stimulation with rIL 2. The phenotype of N-CWS-induced PC with an elevated IL 2 responsiveness was Thy-1.2+(-)-, Lyt-1.1-, Lyt-2.1- and asialo GM1+, suggesting that the N-CWS-stimulated LAK precursors were derived mainly from the NK cell lineage. However, mature T cells may also be involved in this mechanism, because N-CWS failed to augment the IL 2 responsiveness of nonadherent PC in BALB/c nu/nu mice. Treatment of C57BL/6N mice bearing solid Lewis lung carcinoma (3LL) tumors with an intratumoral injection of N-CWS followed by 6 daily sc injections of rIL 2 resulted in the apparent suppression of tumor growth, while N-CWS or rIL 2 alone produced no such suppression. These results suggest that N-CWS augments the antitumor effect of rIL 2 by accumulating LAK precursors and elevating their responsiveness to rIL 2 at the injection site.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2514171      PMCID: PMC5917915          DOI: 10.1111/j.1349-7006.1989.tb02264.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


lymphokine‐activated killer colony‐stimulating factor fetal bovine serum interferon interleukin 2 macrophage‐activating factor Nocardia rubra cell wall skeleton natural killer peritoneal cells recombinant interleukin 2 tumor necrosis factor
  22 in total

1.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

2.  Adjuvant and antitumor activities of Nocardia cell-wall skeletons.

Authors:  I Azuma; T Taniyama; M Yamawaki; K Sugimura; Y Yamamura
Journal:  Gan       Date:  1976-10

3.  Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; S L Schwarz; P J Spiess
Journal:  J Natl Cancer Inst       Date:  1988-11-02       Impact factor: 13.506

4.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

Authors:  R Lafreniere; S A Rosenberg
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

5.  Association of macrophage activation with antitumor effect on rat syngeneic fibrosarcoma by Nocardia rubra cell wall skeleton.

Authors:  T Ogura; N Namba; F Hirao; Y Yamamura; I Azuma
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

6.  Mechanism(s) of in vitro macrophage activation with Nocardia rubra cell wall skeleton: the effects on macrophage activating factor production by lymphocytes.

Authors:  T Masuno; S Hayashi; M Ito; T Ikeda; T Ogura; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.

Authors:  S Hinuma; K Naruo; K Ootsu; T Houkan; O Shiho; K Tsukamoto
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

8.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

9.  Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.

Authors:  L B Owen-Schaub; J U Gutterman; E A Grimm
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

10.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  1 in total

1.  Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells.

Authors:  I Kawase; T Shirasaka; T Ikeda; H Hara; Y Tanio; M Watanabe; S Saito; T Masuno; S Kishimoto; Y Yamamura
Journal:  Jpn J Cancer Res       Date:  1989-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.